Lates News

After Novo Nordisk withdrew from concerns over regulatory risks, Pfizer announced a deal to acquire the obesity drug developer Metsera for over 100 billion US dollars, which will enable Pfizer to re-enter the weight loss drug market. In early trading on Monday, Pfizer rose by 0.8% and Novo Nordisk by 1.2% on the US stock market.